Table 1.
Baseline characteristics | HIV-2 infected patients initiating ART | ||||||
---|---|---|---|---|---|---|---|
| |||||||
Men | Women | Total | P* | ||||
723 | (39.6%) | 1 102 | (60.4%) | 1 825 | (100%) | ||
Age years, median (IQR) | 48.8 [42.9 – 54.6] | 42.6 [35.9 – 49.8] | 45.4 [38.0 – 52.0] | 0.000 | |||
16–39 | 131 | 18.1 | 437 | 39.7 | 568 | 31.1 | |
40–49 | 288 | 39.8 | 396 | 35.9 | 684 | 37.5 | |
≥50 | 304 | 42.1 | 269 | 24.4 | 573 | 31.4 | |
WHO Clinical stage n (%) | 0.180 | ||||||
I and II | 261 | 36.1 | 402 | 36.5 | 663 | 36.3 | |
III and IV | 97 | 13.4 | 117 | 10.6 | 214 | 11.7 | |
Missing | 365 | 50.5 | 583 | 52.9 | 948 | 52.0 | |
Initial CD4 cell count, median (IQR) cells/mm3 | 160 [79 – 262] | 204 [105 – 337] | 185 [95 – 297] | 0.000 | |||
0 – 49 | 73 | 10.1 | 86 | 7.8 | 159 | 8.7 | |
50 – 99 | 88 | 12.2 | 99 | 9.0 | 187 | 10.2 | |
100 – 199 | 148 | 20.5 | 201 | 18.2 | 349 | 19.1 | |
200 – 349 | 136 | 18.8 | 227 | 20.6 | 363 | 19.9 | |
≥350 | 60 | 8.3 | 179 | 16.2 | 239 | 13.1 | |
Missing | 218 | 30.2 | 310 | 28.1 | 528 | 28.9 | |
Initial ART regimen | 0.018 | ||||||
PI-based regimen | 507 | 70.1 | 709 | 64.3 | 1216 | 66.6 | |
Triple NRTI-based regimen | 68 | 9.4 | 105 | 9.5 | 173 | 9.5 | |
Sub optimal ART regimen** | 148 | 20.5 | 288 | 26.2 | 436 | 23.9 | |
BMI, median (IQR) Kg/m2 | 0.015 | ||||||
<18 | 88 | 12.2 | 103 | 9.3 | 191 | 10.4 | |
18 – 25 | 199 | 27.5 | 273 | 24.8 | 472 | 25.9 | |
>25 | 52 | 7.2 | 117 | 10.6 | 169 | 9.3 | |
Missing | 384 | 53.1 | 609 | 55.3 | 993 | 54.4 | |
Haemoglobin level n (%) g/dL | 0.000 | ||||||
<7.5 | 51 | 7.1 | 81 | 7.4 | 132 | 7.2 | |
7.5 – 9.9 | 98 | 13.5 | 216 | 19.6 | 314 | 17.21 | |
10 – 12 | 134 | 18.5 | 266 | 24.1 | 400 | 21.9 | |
>12 | 168 | 23.2 | 128 | 11.6 | 296 | 16.2 | |
Missing | 272 | 37.6 | 411 | 37.3 | 683 | 37.4 | |
Year of ART initiation | 0.000 | ||||||
<2007 | 249 | 34.4 | 277 | 25.1 | 526 | 28.8 | |
2007–2010 | 201 | 27.8 | 345 | 31.3 | 546 | 29.9 | |
2011–2014 | 273 | 37.8 | 480 | 43.6 | 753 | 41.3 |
IQR: Interquartile Range; ART: Antiretroviral therapy; BMI: Body mass index; Hb: Haemoglobin; p*: p-value indicating a significant difference between men and women for the considered variable;
Sub optimal regimen indicative of patients initially miss-diagnosed and treated as HIV-1.